FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.

CVS also announced that AbbVie and CVS-owned company Cordavis, which launched in August, will produce a co-branded version of Humira that will be made available to customers in the second quarter of ...

Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So ...

Humira has been one of the world's top selling drugs for more than two decades. But thanks to some new copycats — including one that is being sold at entrepreneur Mark Cuban's online pharmacy — its ...

AbbVie did not immediately respond to a request for comment, but has previously said it expects to retain a lower share of the Humira market next year. Pharmacy benefit managers, which act as ...

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie 's Humira are plummeting as the once-top-selling drug fights ...

As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially ...

Humira (adalimumab) is a prescription drug used to treat hidradenitis suppurativa (HS). It helps reduce moderate to severe symptoms of this condition. Humira is also available in biosimilar forms.

Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction thanks ...

(Reuters) - CVS Health said on Wednesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April 1, and will ...